85650-56-2
Chemical Structure
Asenapine maleate
Synonym(s): Org 5222 maleate
- CAS No.: 85650-56-2
- Formula:C21H20ClNO5
- Molecular Weight:401.84
IUPAC Name: (3aS,12bS)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole maleate
InChIKey: GMDCDXMAFMEDAG-CHHFXETESA-N
SMILES: CN1C[C@]2([H])C3=CC=CC=C3OC4=CC=C(Cl)C=C4[C@]2(C1)[H].O=C(O)/C=C\C(O)=O
Biological Activity: Asenapine (Org 5222) maleate, a brain-penetrant atypical antipsychotic, is an antagonist of serotonin receptors (pKi: 8.4-10.5), adrenoceptors (pKi: 8.9-9.5), dopamine receptors (pKi: 8.9-9.4) and histamine receptors (pKi: 8.2-9.0). Asenapine maleate can be used in the research of schizophrenia and bipolar disorder[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Asenapine maleate | 99.95% | Asenapine (Org 5222) maleate, a brain-penetrant atypical antipsychotic, is an antagonist of serotonin receptors (pKi: 8.4-10.5), adrenoceptors (pKi: 8.9-9.5), dopamine receptors (pKi: 8.9-9.4) and histamine receptors (pKi: 8.2-9.0). Asenapine maleate can be used in the research of schizophrenia and bipolar disorder. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Asenapine maleate (Standard) | ≥98% | Asenapine maleate (Standard) is the analytical standard of Asenapine (maleate) (HY-11100). This product is intended for research and analytical applications. Asenapine (Org 5222) maleate, a brain-penetrant atypical antipsychotic, is an antagonist of serotonin receptors (pKi: 8.4-10.5), adrenoceptors (pKi: 8.9-9.5), dopamine receptors (pKi: 8.9-9.4) and histamine receptors (pKi: 8.2-9.0). Asenapine maleate can be used in the research of schizophrenia and bipolar disorder. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Shahid M, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009 Jan;23(1):65-73. [Content Brief]
- [2]. Olivia Frånberg, et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl). 2008 Feb;196(3):417-29. [Content Brief]
- [3]. Ohyama M,et al. Asenapine reduces anxiety-related behaviours in rat conditioned fear stress model. Acta Neuropsychiatr. 2016 Dec;28(6):327-336. [Content Brief]
- [4]. Ene HM, et al. Effects of repeated asenapine in a battery of tests for anxiety-like behaviours in mice. Acta Neuropsychiatr. 2016 Apr;28(2):85-91. [Content Brief]
- [5]. Stoner SC, et al. Asenapine: a clinical review of a second-generation antipsychotic. Clin Ther. 2012 May;34(5):1023-40. [Content Brief]
